GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ ® Named Early Access Program (AAC) in France
PARIS--(BUSINESS WIRE)--Regulatory News:
GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that it has reached agreement with the French medicines safety agency ANSM to consider expeditiously opening the French named early access program (AAC) for LUMEVOQ ® upon approval of a dose-ranging clinical study.
Clear Path Forward for LUMEVOQ ® AAC Program in France
Following extensive discussions, GenSight reached alignment with ANSM on a plan to open the LUMEVOQ ® AAC program. The agency has agreed that the authorization of a focused dose-ranging study could enable the opening of the early access program. The Company has submitted a preliminary design of the study to the agency and aims to finalize the protocol of a dose-ranging study in Q3 2025.
In parallel, the Company will work with the agency to find a solution for patients who may not be included in the study but who may benefit from the AAC program. The AAC program is targeted to open in Q4 2025 at the latest.
"In the interest of clearing the way for patients to be treated with LUMEVOQ, we are pleased to have achieved this important agreement with ANSM on a clear path forward for opening patient access to LUMEVOQ in France" said Laurence Rodriguez, Chief Executive Officer of GenSight Biologics."We are thankful for the ANSM's ongoing engagement and openness to discussion, as we work towards the shared goal of providing access to LHON patients who urgently need a safe and effective treatment."
Financing Strategy to Support Regulatory Milestones
GenSight is implementing a financing strategy to bridge operations through the opening of the AAC program and prepare for the new global Phase III clinical trial. The Company is actively pursuing various funding initiatives to support these critical regulatory milestones.
' We are working on our financing strategy to manage the bridge between now and the opening of the AAC program and the initiation of the Phase III study,' commented Jan Eryk Umiastowski, CFO of GenSight Biologics. "Our focus remains on securing the resources needed to execute our regulatory strategy while exploring additional funding opportunities."
Advancing Core Marketing Authorization Strategy
In parallel with the French AAC program developments, GenSight will continue to advance its global marketing authorization strategy:
Preparation for regulatory consultations in the US and EU
Planning for the global Phase III trial scheduled to begin in 2026, designed to meet FDA and EMA requirements
Completing the transition to a new manufacturing partner to secure reliable clinical and commercial supply
Advancing preparations for MHRA submission in the United Kingdom
During this period, the Company will actively pursue additional non-dilutive funding opportunities, including licensing arrangements outside North America and Europe and potential M&A activities.
Multiple Value Catalysts
GenSight anticipates a number of significant value-creating events in 2025-2026:
Financial Position
The Company received €0.7 million of its Research Tax Credit (CIR) end of May, with the remaining €0.4 million to be paid in July 2025. Based on current operations and projections, GenSight's cash will support operations until mid-July 2025.
The Company acknowledges that current funds are insufficient to cover operational requirements for the next 12 months. The planned financing initiatives are designed to extend the cash runway and enable the initiation of the Phase III clinical trial and UK MHRA marketing application for LUMEVOQ ®.
As of June 12, 2025, the number of outstanding GenSight Biologics shares was 131,466,495 ordinary shares.
Risk factors
Detailed information regarding the Company, including its business, financial information, results, perspectives and related risk factors are contained (i) in the Company's 2024 Universal Registration Document filed with the AMF on April 8, 2025 under number D.25-0234. This document, as well as other regulated information and all of the Company's press releases, can be accessed on the Company's website (www.gensight-biologics.com) and/or AMF (www.amf-france.org). The reader's attention is drawn to the risk factors related to the Company and its activities presented in chapter 3 of its 2024 URD in particular the liquidity risk presented in the chapter 3.1.1.
About GenSight Biologics
GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, GS010 (lenadogene nolparvovec) is in Phase III in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding product development prospects and financial projections. These statements do not constitute guarantees of future performance and involve risks and uncertainties. While the Company is actively pursuing financing solutions, regulatory requirements necessitate disclosure that material uncertainty exists regarding the Company's ability to continue as a going concern if sufficient funding cannot be secured. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in GenSight Biologics' regulatory filings with the French Autorité des Marchés Financiers. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, GenSight Biologics undertakes no obligation to update or revise the information contained in this press release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
24 minutes ago
- Business Wire
Vestis Investors Have the Opportunity to Lead the Vestis Securities Fraud Lawsuit With Faruqi & Faruqi, LLP
NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Vestis Corporation ('Vestis' or the 'Company') (NYSE: VSTS) and reminds investors of the August 8, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Vestis' ability to grow its business; notably that Vestis would be unable to execute on planned strategic initiatives to drive purported improvements to the customer experience and its onboarding efforts in order to drive new customer growth, increased customer retention, and increased revenue from existing customers. On May 7, 2025, Vestis announced its financial results for the second quarter of fiscal 2025, withdrew its revenue and growth guidance for the full fiscal year 2025, and provided guidance for the third quarter of fiscal 2025 that fell significantly below market expectations. The Company attributed its poor results partially to 'lost business in excess of new business,' but primarily on 'lower adds over stops, which is how we describe volume changes with our existing customers.' The Company attributed its decision to pull full-year guidance and provide disappointing third quarter targets to the 'increasingly uncertain macro environment.' Following this news, the price of Vestis' common stock declined dramatically. From a closing market price of $8.71 per share on May 6, 2025, Vestis' stock price fell to $5.44 per share on May 7, 2025, a decline of about 37.54% in the span of just a single day. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Vestis' conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Vestis Corporation class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
Yahoo
25 minutes ago
- Yahoo
Paris Air Show goes big on defense amid war concerns
PARIS — The Paris Air Show, the biggest event of its kind by number of exhibitors, will feature significantly more defense themes at this year's edition compared to two years ago, driven by a deteriorating global security situation, the show organizers said. About 45% of the show will be dedicated to defense and security, a 'strong increase' from the previous show in 2023, with the remainder focused on civil aerospace, the general commissioner of the show, Emmanuel Viellard, said at a press briefing here last week by the French Aerospace Industries Association, or Gifas, which runs the event. The week-long show kicks off on Monday. This year's edition of the world's oldest air show comes as Russia's invasion of Ukraine is in its fourth year, and as NATO Secretary General Mark Rutte calls for higher defense budgets to deal with a more dangerous world that includes a threatening Russia and expanding China. European NATO members' spending plans include more drones, air and missile defense and air power. In addition, Israel's strikes on Iranian nuclear and military facilities in the early morning hours of June 13 have diplomats and military officials on edge. 'We are in a much more conflict-ridden environment, with increased attention on security issues, and therefore greater activity in the defense sector compared to what we saw in 2023,' Guillaume Faury, the CEO of Airbus and president of Gifas, said at last week's press briefing. The event is held every two years at Le Bourget Airport north-east of the French capital, with the French commonly referring to the show as the Salon de Bourget. The first Paris edition was held in the heart of the city in 1909, at the time called the Salon de la Locomotion Aérienne. Many industry stakeholders see this year's show as a place to meet military brass, defense ministries and industrial partners 'to discuss security issues and prospects for increased defense spending in Europe.' Faury said. Likewise, national delegations and military representatives expect to be able to meet with 'all the players in this sector' in Paris, he said. NATO has singled out air defense as a priority, with Rutte saying earlier this week alliance members need to boost their air and missile defenses fivefold to counter the threat from Russia. Among this year's Paris Air Show exhibitors, Raytheon will brief visitors on the Patriot surface-to-air missile system, Diehl Defence will present its IRIS-T system, while other air-defense suppliers signed up for the show include pan-European missile maker MBDA and Norway's Kongsberg. Around 200 military delegations will attend the event, according to the organizers. The 2023 edition of the biennial show drew nearly 293,000 visitors, including some 127,000 professionals. This year's edition will feature 2,400 exhibitors, including around 1,110 from France, 450 from the United States, 120 from Italy and around 100 from both the U.K. and Germany, the show runners said. The Paris Air Show will host 83 of the world's top 100 aerospace companies, compared to 57 for the U.K.'s Farnborough Air Show, said Guillaume Bourdeloux, the CEO of the air show. Visitors will be able to see some 150 aircraft, with flying demonstrations of the Dassault Aviation Rafale, the Eurofighter Typhoon and Lockheed Martin's F-35, as well as other aircraft. The French Air and Space Force will display an Airbus A400M military transport at the show, and will operate a temporary air base with air and drone defenses to secure the skies over Le Bourget. The French armed forces exhibit will also include two variants of the Rafale fighter jet including the carrier version, an Airbus Helicopters H225M Caracal tactical transport helicopter and a SAMP/T air defense system fitted with MBDA's Aster missile.
Business Wire
30 minutes ago
- Business Wire
RCKT Investors Have the Opportunity to Lead the Rocket Pharmaceuticals Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rocket Pharmaceuticals, Inc. ('Rocket' or the 'Company') (NASDAQ: RCKT) and reminds investors of the August 11, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RP-A501's safety and clinical trial protocol; notably, that Rocket knew Serious Adverse Events (SAEs), including death of participants enrolled in the study, were a risk. In particular, Rocket amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Rocket's securities at artificially inflated prices. On May 27, 2025, Rocket announced that the FDA placed a clinical hold on the RP-A501 Phase 2 pivotal study after at least one patient suffered a Serious Adverse Event (SAE), ultimately, death, while enrolled in the study following a substantive amendment to the protocol that the Company failed to disclose to investors at the time management made the revision. In fact, Rocket stated that, while the patient was dosed in May, the decision to amend the protocol was made 'several months' earlier. Despite this, Rocket made no attempt to alert investors or the public to the change until after the SAE occurred. Following this news, the price of Rocket's common stock declined dramatically. From a closing market price of $6.27 per share on May 23, 2025, Rocket's stock price fell to $2.33 per share on May 27, 2025, a decline of about 37% in the span of just a single trading day. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Rocket's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Rocket Pharmaceuticals class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
